Enteral controlled-release opioid delivery systems

Pain Medicine

Volumn 10, Issue SUPPL. 1, 2009, Pages

  Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Alcohol; ECRO; Enteral controlled release opioid delivery systems; Opioids; Oxymorphone

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; MORPHINE SULFATE; MSCONTIN; OPANA ER; OPIATE; OXYCODONE; OXYMORPHONE; POLYMER; PRICARA; SUFENTANIL; TRAMADOL; UNCLASSIFIED DRUG; XANTHAN;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG SOLUTION; ENTERAL DRUG ADMINISTRATION; HYDROPHILICITY; HYDROPHOBICITY; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; REVIEW; SPINAL DRUG ADMINISTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 64249144111     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00597.x     Document Type: Review

References (34)

1. Staniforth JN, Baichwal AR. TIMERx ®: Novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract. Expert Opin Drug Deliv 2005; 2: 587-95.
2. Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet 1998; 35: 173-90.
3. Ligand Pharmaceuticals. Avinza (Morphine Sulfate). Package Insert. San Diego, CA: Author; February 2003.
4. Alpharma Branded Products Division. Kadian (Morphine Sulfate). Package Insert. Piscataway, NJ: Author; November 2004.
5. Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained release morphine formulation with standard oral morphine. J Pain Symptom Manage 1997; 14: 63-73.
6. Portenoy RK, Sciberras A, Eliot L, et al. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 2002; 23: 292-300.
7. Data on File. Stanford, CT: Purdue Pharma LP.
8. Langer R. Polymer-controlled drug delivery systems. Acc Chem Res 1993; 26: 537-42.
9. Purdue Fredrick. MSContin (Morphine Sulfate). Package Insert. Stamford, CT: Purdue Fredrick; December 2004.
10. Wilkinson K. Cancer treatments. Clin J Oncol Nurs 2003; 7: 458-60.
11. Leslie S. The Contin delivery system: Dosing considerations. J Allergy Clin Immunol 1986; 78: 768-73.
12. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th edition. Glenview, IL: American Pain Society; 2003.
13. Broomhead A, West R, Eglinton L, et al. Comparative single-dose pharmacokinetics of sustained-release and modified-release morphine sulfate capsules under fed and fasting conditions. Clin Drug Investig 1997; 13: 162-70.
14. Maccarone C, West RJ, Broomhead AF, Hodsman GP. Single dose pharmacokinetics of Kaponol ®, a new oral sustained-release morphine formulation. Drug Invest 1994; 7: 262-74.
15. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MSContin in the treatment of severe cancer pain. Pain 1997; 69: 295-302.
16. Wilkinson K. Cancer treatments. Clin J Oncol Nurs 2003; 7: 458-60.
17. Endo Pharmaceuticals. Data on File. Chadds Ford, PA: Author; 2003.
18. Staniforth JN, Baichwala A. Synergistically interacting heterodisperse polysaccharides-function in achieving controllable drug delivery. American Chemical society. In: El-Nokaly M, Platt D, Charpentier B, eds. Polymorphis Delivery Systems: Properties and Applications. Washington, DC: American Chemical Society; 1993.
19. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Brit J Clin Pharmacol 1996; 42: 747-56.
20. Wallace M, Rauck RL, Moulin D, et al. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res 2008; 36: 343-52.
21. Purdue Pharma LP. Suspends marketing of Palladone capsules. Purdue Pharma press release. 2005. Available at: http://www.pharma.com/ pressroom/news/20050713-01.pdf (accessed July 2005).
22. Purdue Pharma L.P. Palladone (Hydromorphone). Package Insert. Stamford, CT: Author; November 2004.
23. Hydromorphone hydrochloride extended-release capsules: Alcohol-palladone interaction. FDA alert for healthcare professionals. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/hydromorphoneHCP.pdf (accessed July 2005).
24. Meyer RJ, Hussain AS. Awareness topic: Mitigating the risks of ethanol induced dose dumping from oral sustained/controlled release dosage forms. FDA Advisory Committee for Pharmaceutical Services Meeting, 2005.
25. US Food and Drug Administration. Palladone (Hydromorphone Hydrochloride Extended-Release) Capsules: Questions and Answers. Author; 2005.
26. King Pharmaceuticals, Inc. AVINZA [Package Insert]. Bristol, TN: Author; 2006.
27. Ligand Pharmaceuticals Inc. Dear Health Care Professional Letter. San Diego, CA: Author; 2005.
28. Endo Pharmaceuticals Inc. OPANA ER [Package Insert]. Chadds Ford, PA: Author; 2007.
29. Endo Pharmaceuticals. Oxymorphone Hydrochloride, Extended-Release (Opana ER) Product Information. Chadds Ford, PA: Author; 2006.
30. Endo Pharmaceuticals. Oxymorphone Hydrochloride (Opana) Product Information. Chadds Ford, PA: Author; 2006.
31. Johnson F, Wagner G, Sun S, Stauffer J. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. The Journal of Pain 2008; 9: 330-6.
32. US Food and Drug Administration. Letter to Alpharma Pharmaceuticals NDA 20-616/S-017 and S-021. Rockville, MD: Author; 2007.
33. Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008; 24: 297-305.
34. Traynor MJ, Brown MB, Pannala A, Beck P, Martin GP. Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments. Drug Dev Ind Pharm 2008; 34: 885-9.